SARMopathy and Axon Degeneration
SARMopathy refers to a disease process driven by activation of a protein called SARM1 (Sterile Alpha and TIR Motif Containing 1), which acts as a key executioner of axon degeneration. For a long time, axon loss in neurological disease was thought to be a passive consequence of injury or cell death. Work led by Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio fundamentally changed that view by showing that axons can activate a regulated self-destruction program. In this model, axon degeneration is not simply accumulation of damage, but an active, enzyme-driven process. This pathway is now understood to play a role in a wide range of conditions, including peripheral neuropathy, traumatic brain injury, ischemic stroke, and potentially aspects of ALS and other neurodegenerative diseases. Because it represents a final common execution step, it has become a major target for therapeutic intervention.
Normal Biology
Under normal conditions, axons maintain their integrity through a balance of metabolic support and protective signaling. A key player in this system is NMNAT2, an enzyme that helps maintain levels of NAD+, a crucial metabolic cofactor. NMNAT2 is continuously transported along the axon from the cell body, and as long as this supply is maintained, axons remain stable. In this state, SARM1 is present but inactive because of high levels of NAD+, and the axon remains healthy. This system acts as a kind of metabolic checkpoint. If the axon is intact and well-supported, NMNAT2 levels stay high and SARM1 remains suppressed. If the axon is damaged or stressed, NMNAT2 levels can fall, removing this protective signal. This setup allows axons to rapidly respond to severe damage by activating a controlled breakdown process, which may be beneficial in certain contexts such as development or injury cleanup.
SARM1 Activation
SARMopathy begins when the balance between NMNAT2 and SARM1 is disrupted. When NMNAT2 levels fall, either due to physical injury, impaired transport, metabolic stress, or toxic exposure, SARM1 becomes activated. Once activated, SARM1 rapidly breaks down NAD+, leading to a collapse in the axon’s energy state. This triggers a cascade of events: loss of ATP production, disruption of ion homeostasis, calcium influx, and activation of proteases and cytoskeletal breakdown. Importantly, this process is self-propagating and irreversible once initiated. The axon fragments in a stereotyped pattern, similar to what is seen in Wallerian degeneration after nerve injury. What makes this pathway especially important is that it can be triggered not only by physical injury, but also by metabolic and toxic stress, linking it to many disease contexts.
Disease Connections
SARM1-mediated axon degeneration is increasingly recognized across a range of neurological conditions. In chemotherapy-induced peripheral neuropathy (CIPN), multiple studies show that SARM1 is required for axon degeneration triggered by agents such as paclitaxel and cisplatin. Blocking SARM1 in preclinical models protects axons and reduces neuropathy. In traumatic brain injury (TBI), axonal damage is a central feature, and SARM1 activation contributes to ongoing white matter degeneration after the initial injury. In ischemic stroke, emerging evidence suggests that SARM1 contributes to delayed axonal degeneration in affected brain regions, potentially influencing long-term outcomes. In ALS, long motor axons are particularly vulnerable, and SARM1-mediated degeneration has been implicated as a potential contributor to disease progression, though this is still being actively studied. More broadly, SARMopathy provides a framework for understanding how diverse upstream insults, including mitochondrial dysfunction, ROS, and impaired transport, can converge on a common degenerative endpoint.
Molecular Consequences
The central molecular event in SARMopathy is rapid depletion of NAD+. SARM1 has intrinsic enzymatic activity that breaks down NAD+ into signaling molecules such as cyclic ADP-ribose (cADPR). This leads to a collapse in the metabolic state of the axon, since NAD+ is essential for energy production and redox balance. Loss of NAD+ disrupts mitochondrial function, ATP production, and ion gradients. Calcium levels rise, activating enzymes that degrade cytoskeletal components and membranes. This process is tightly linked to mitochondrial dysfunction and ROS, as energy failure and oxidative stress reinforce each other. It also intersects with PARP signaling in response to DNA damage, where excessive activation of PARP enzymes can consume NAD+ and further promote degeneration. The result is a rapid and coordinated breakdown of the axon, transforming it from a functional structure into fragmented debris.
Therapeutic Targeting
SARM1 is one of the most promising therapeutic targets in neurodegeneration because it sits at a clear, well-defined execution point. In preclinical models, deletion or inhibition of SARM1 provides strong protection against axon degeneration across multiple injury and disease contexts. This has led to the development of SARM1 inhibitors as potential therapies. One example is work emerging from Disarm Therapeutics (now part of Eli Lilly), which is developing small-molecule SARM1 inhibitors. Early-stage clinical efforts, including participation in the Healey ALS Platform Trial, reflect growing interest in translating this pathway into human therapy. Another strategy is to enhance upstream protective mechanisms, such as stabilizing NMNAT2 or boosting NAD+ metabolism. These approaches aim to prevent SARM1 activation rather than blocking it directly. While these therapies are still in development, SARM1 represents one of the clearest examples of a mechanistically grounded target with broad applicability across neurological diseases.
Research Directions
Research on SARMopathy is rapidly expanding, with several key directions. One major focus is understanding how different stressors, including mitochondrial dysfunction, oxidative stress, and impaired axonal transport, converge to activate SARM1. This may help identify upstream intervention points. Another area of interest is the relationship between SARM1 and other NAD+-consuming pathways, particularly PARP signaling. This connection may help explain how DNA damage and metabolic stress can trigger axon degeneration. There is also ongoing work to develop and refine SARM1 inhibitors, including improving their specificity, brain penetration, and safety. Translating strong preclinical results into effective human therapies is a major goal. Finally, researchers are exploring whether partial or transient inhibition of SARM1 could preserve axons without interfering with beneficial processes such as developmental pruning or injury response. Overall, SARMopathy represents a shift in thinking: axon loss is not just damage, but a regulated biological process that may be interruptible.
Sources
- Osterloh, J. M., Yang, J., Rooney, T. M., et al. (2012). dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.
- Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2015). SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
- Figley, M. D., & DiAntonio, A. (2020). The SARM1 axon degeneration pathway: control of the NAD⁺ metabolome regulates axon survival in health and disease.
- Coleman, M. P., & Höke, A. (2020). Programmed axon degeneration: from mouse to mechanism to medicine.
- Sasaki, Y., Engber, T. M., Hughes, R. O., et al. (2020). cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons.